CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

encorafenib and binimetinib

Last Updated: November 17, 2020
Result type: Reports
Project Number: PC0232-000
Product Line: Reimbursement Review

Generic Name: encorafenib and binimetinib

Brand Name: Braftovi and Mektovi

Manufacturer: Pfizer Canada ULC

Therapeutic Area: Advanced Melanoma

Indications: ​Braftovi (encorafenib): In combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Mektovi (binimetinib): In combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Manufacturer Requested Reimbursement Criteria1: ​Braftovi (encorafenib): In combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Mektovi (binimetinib): In combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Submission Type: Initial

Tumour Type: Skin & Melanoma

Project Status: Pending

Call for patient/clinician input open: November 17, 2020

Call for patient/clinician input closed: January 15, 2021

Anticipated Date: December 15, 2020

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback